“The Endura Embolization Device covers the aneurysm neck and provides a platform to embolize the remainder of the aneurysm sac,” said Dr. Baxter, an investor and consultant to the Company. “I am pleased to be the first to present the Endura technology to my peers. It is exciting to have this promising option on the horizon, and I believe it has the potential to significantly improve outcomes for patients with cerebral aneurysms,” added Baxter.
The Endura Embolization System consists of a detachable accessory balloon and soft platinum coils. The combination of coils and a balloon has the potential to provide immediate cerebral aneurysm occlusion, reduce the risk of coil prolapse, and promote endothelialization of the aneurysm neck by presenting a flat, solid surface at the aneurysm neck. Funded by a Phase I SBIR grant from the National Institute of Neurological Disorders and Stroke at the National Institutes of Health, the study compared the efficacy of the Endura Embolization System to coil-only treatments for the occlusion of aneurysms in a challenging model of terminal bifurcation aneurysms.
“We are pleased the Endura technology was presented at this year’s ABC-WIN conference which provided an excellent opportunity to engage with physicians,” said Dr. F. Nicholas Franano, President and CEO of Artio. “Many difficult clinical cases were presented, highlighting the challenges associated with current commercially available devices. The feedback received on the Endura System was very encouraging, and we are increasingly confident in the clinical and commercial potential of Artio’s aneurysm occlusion devices.”